The imperative for disease modifying treatments in Alzheimer's disease.
Gallagher
D
D
Mhaolain
A Ni
AN
Lawlor
B
B
D000544:Alzheimer Disease / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000187:drug effects / Q000276:immunology*; D018450:Disease Progression; D038341:Glycogen Synthase Kinases / Q000037:antagonists & inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007167:Immunotherapy; D007494:Ireland / Q000453:epidemiology; D012307:Risk Factors
D016229:Amyloid beta-Peptides; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D038341:Glycogen Synthase Kinases